Natural favonols: actions, mechanisms, and potential therapeutic utility for various diseases
Microbiome Signatures identifies and validates condition-specific microbiome shifts and interventions to accelerate clinical translation. Our multidisciplinary team supports clinicians, researchers, and innovators in turning microbiome science into actionable medicine.
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease—four years before the first published case study.
The review investigated the biological and medicinal importance of flavonols, particularly their roles in disease prevention and treatment. The focus was on their antioxidative properties and their potential therapeutic utility against diabetes, cancer, cardiovascular diseases, and microbial infections.
The key findings highlighted the protective roles of flavonols such as quercetin, myricetin, kaempferol, and fisetin against oxidative damage, their effectiveness in inhibiting tumor growth, improving insulin secretion, and acting as alternatives to conventional antibiotics by blocking viral entry and restricting viral infection.
The study’s greatest implications emphasize flavonols’ potential to significantly reduce the risk of chronic diseases like cancer and coronary diseases, suggesting their integration into dietary strategies and therapeutic approaches. This could lead to developments in how dietary flavonols are recommended for disease prevention and management in clinical practices.